Build more efficient spreadsheets by using the dollar sign to lock specific rows, columns, or permanent addresses when ...

Progress was made in Connecticut Friday on a bill that looks to ban cellphone use in public schools. Not all parents agree on the strategy, however. Industry reaction to US Supreme Court ruling on ...

Scientists have discovered why ovarian cancer spreads so rapidly through the abdomen. Cancer cells enlist normally protective abdominal cells, forming mixed groups that work together to invade new ...

Comcast topped analyst estimates on adjusted earnings when it reported its fourth-quarter financials on Thursday. However the cable giant slightly missed Wall Street’s expectations for quarterly ...

New York City Mayor Zoran Mamdani made reference to New York Knicks star point guard Jalen Brunson during the mayor's inaugural speech on Thursday, and even appeared to make a gesture that resembled ...

A Texas teenager was rescued by her father after she was forced into a truck at knifepoint on Christmas Day, police said. Patrol deputies with the Montgomery County Sheriff's Office were called to an ...

Scientists have captured a never-before-seen, high-resolution look at influenza’s stealthy invasion of human cells, revealing that the cells aren’t just helpless victims. Using a groundbreaking ...

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) ranks among the most oversold biotech stocks to invest in. On November 20, Leerink Partners upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) from Market ...

Shares of Agios Pharmaceuticals AGIO tanked about 51% on Wednesday after it reported mixed top-line results from the phase III RISE UP study, which evaluated orally administered Pyrukynd (mitapivat) ...

While mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance. 40.6% of ...

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle ...